Good Documentation Practice (GDP) for Pharma & Medical Device Companies: Updated for CSA (2025), QMSR (2026), and the First 483-Response Guidance (Mar

By GRC Times

If it isn't documented, it didn't happen.

In pharmaceutical, medical device, and other FDA-regulated industries, your documentation isn't paperwork, it's the evidence that proves your product is safe, your process is controlled, and your data can be trusted.

Everybody knows it, but every year, FDA and MHRA cite the same documentation failures: incomplete batch records, missing audit trails, unattributable data, weak CAPAs with no effectiveness evidence, and the gap between what the SOP says and what people actually do. These aren't process failures, but are documentation failures, and they're preventable.

This is the most current GDP field guide available, updated for recent unprecedented regulatory change:

The finalized Computer Software Assurance (CSA) framework (September 2025)The Quality Management System Regulation (QMSR), effective February 2026FDA's first-ever guidance on responding to 483 observations (March 2026)FDA's first warning letter citing improper AI use in manufacturing (April 2026)

It incorporates the extensive review of current FDA and MHRA enforcement findings and the latest 2025-2026 guidance, it turns expectations into action you can take today.

This is not a restatement of 21 CFR Parts 211 and 212. Written by a group of authors so that you get various perspectives and, It synthesizes requirements scattered across FDA, EMA/EudraLex, ICH, ISO, and USP into one practical reference, covering GDP, GMP, data integrity, CAPA, computer system validation, quality systems, and ISO 13485. The whole picture, not a single slice.

WRITTEN FOR EVERYONE WHO TOUCHES A GXP RECORDQA and QC managers, reviewers, and quality engineersProduction supervisors and manufacturing operatorsLaboratory analysts and lab managersRegulatory Affairs professionalsIT and Computer System Validation (CSV/CSA) teamsNew hires, career changers, and trainers building onboarding material

A junior engineer can read it Monday and contribute by Friday. QA leaders can use it as ready-made training, no need to build materials from scratch.

WHAT YOU'LL LEARN

Apply ALCOA+ as daily behavior, not a memorized acronymComplete and review batch records that withstand scrutinyCorrect errors and handle late entries without creating violationsBuild CAPAs with documented root cause and effectiveness evidence FDA trustsIdentify data integrity gaps before an inspector doesValidate computerized systems under the new CSA frameworkHandle Part 11, LIMS, EBR, and audit trail review with confidenceStructure a 483 response that closes the matter instead of triggering a Warning LetterReduce inspection risk and build genuine inspection confidence

WHAT'S INSIDE

12 chapters covering the full documentation lifecycle - from why it matters to inspection dayAnnotated "good vs. bad" examples with images on every high-risk topicReference tables, decision trees, and the decision frameworkA data integrity maturity model and the five CAPA anti-patternsStrong-vs-weak CAPA and 483 response examples, side by sideInfographics you can photocopy and paste in your desk or wallImages you can use for your presentations or trainingA 150-term glossary with regulatory anchors and practitioner context

This can be a good addition for your library, any new joiner must go through it.

Stronger records. Cleaner data. Provable quality. Start building them now.

• Format: Paperback
• Language: English
• ISBN: B0H4KFP9S5
• ISBN13: 9798180475732
• Release Date: June 2026
• Publisher: Independently Published
• Length: 316 Pages
• Weight: 0.93 lbs.
• Dimensions: 0.7" x 6.0" x 9.0"